Vertex Pharmaceuticals Incorporated
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vertex Pharmaceuticals Incorporated
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.
Coming Up On US FDA’s User Fee Calendar: Zynteglo Approval Kicks Off Busy Season For Advanced Biologics, Pediatrics
At least 17 applications are pending with late August and September 2022 user fee goal dates, the Pink Sheet US FDA Performance Tracker shows.
- Other Names / Subsidiaries
- ViroChem Pharma Inc., Exonics Therapeutics, Inc., Semma Therapeutics